Published in Neurobiol Dis on August 07, 2007
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
The molecular profile of microglia under the influence of glioma. Neuro Oncol (2012) 2.38
Olfaction in Parkinson's disease and related disorders. Neurobiol Dis (2011) 1.51
Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci (2009) 1.41
The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem (2009) 1.20
Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology (2012) 1.07
Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol Ther (2010) 1.07
ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep (2012) 1.06
Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro (2013) 1.05
Tumor-associated macrophages in glioma: friend or foe? J Oncol (2013) 1.00
Microglia and microglia-like cell differentiated from DC inhibit CD4 T cell proliferation. PLoS One (2009) 0.86
Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neurosci Lett (2013) 0.85
The role of microglia in human disease: therapeutic tool or target? Acta Neuropathol (2014) 0.85
Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice. J Exp Med (2015) 0.84
Differentiation of mouse bone marrow derived stem cells toward microglia-like cells. BMC Cell Biol (2011) 0.83
Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease. Hypertension (2014) 0.81
Microglial phenotypes in Parkinson's disease and animal models of the disease. Prog Neurobiol (2016) 0.80
BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease. PLoS One (2011) 0.79
Histological Architecture Underlying Brain-Immune Cell-Cell Interactions and the Cerebral Response to Systemic Inflammation. Front Immunol (2017) 0.75
In Vivo Growing of New Cell Colonies in a Portion of Bone Marrow: Potential Use for Indirect Cell Therapy. Cell Med (2010) 0.75
Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. J Neuroinflammation (2017) 0.75
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci (2010) 3.05
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol (2010) 2.12
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 2.11
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol (2006) 1.82
The subthalamic nucleus is involved in successful inhibition in the stop-signal task: a local field potential study in Parkinson's disease. Exp Neurol (2012) 1.74
Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc (2012) 1.70
Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord (2014) 1.63
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res (2012) 1.58
Deep brain stimulation for Parkinson's disease: thinking about the long-term in the short-term. Mov Disord (2011) 1.42
Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's disease. Exp Brain Res (2013) 1.36
Deep brain stimulation: from neurology to psychiatry? Trends Neurosci (2010) 1.28
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23
IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord (2011) 1.18
Successful thalamic deep brain stimulation for orthostatic tremor. Mov Disord (2008) 1.17
Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain (2010) 1.15
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09
Continuing efforts to obtain continuous delivery of levodopa. Mov Disord (2011) 1.08
Letter to the editor: Parkinson's disease and early subthalamotomy. J Neurosurg (2015) 1.07
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
Densely granulated murine NK cells eradicate large solid tumors. Cancer Res (2012) 1.04
A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03
Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer (2004) 1.00
Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res (2011) 1.00
Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem (2008) 0.98
Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol (2009) 0.98
Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther (2006) 0.98
Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97
The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation (2011) 0.97
Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol (2010) 0.96
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. Eur J Nucl Med Mol Imaging (2012) 0.94
Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res (2012) 0.94
Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord (2009) 0.94
The pathophysiological basis of sensory disturbances in Parkinson's disease. J Neurol Sci (2009) 0.93
Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol (2007) 0.93
Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer (2011) 0.92
Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther (2010) 0.92
Hardware complications in deep brain stimulation: electrode impedance and loss of clinical benefit. Parkinsonism Relat Disord (2012) 0.91
Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol Ther (2005) 0.91
Interleukin-15 in gene therapy of cancer. Curr Gene Ther (2013) 0.91
The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer (2007) 0.90
How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci (2004) 0.90
Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus. Eur J Neurosci (2004) 0.89
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med (2012) 0.89
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol (2011) 0.89
The subthalamic nucleus and inhibitory control: impact of subthalamotomy in Parkinson's disease. Brain (2014) 0.88
CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J Immunol (2012) 0.88
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord (2009) 0.88
Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation. Clin Cancer Res (2009) 0.87
Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial? Immunotherapy (2009) 0.87
Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur J Immunol (2010) 0.86
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res (2003) 0.86
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One (2012) 0.85
Lymphatic endothelium forms integrin-engaging 3D structures during DC transit across inflamed lymphatic vessels. J Invest Dermatol (2013) 0.85
Clinical and pathological features of Parkinson's disease. Curr Top Behav Neurosci (2015) 0.84
T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes. J Immunol (2013) 0.84
Levodopa toxicity and Parkinson disease: still a need for equipoise. Neurology (2011) 0.84
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord (2009) 0.83
Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson's disease. Parkinsonism Relat Disord (2010) 0.83
CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells. FASEB J (2012) 0.83
Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death. Clin Cancer Res (2003) 0.83
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo. Int J Cancer (2010) 0.83
When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol (2010) 0.83
Cell tracking using multimodal imaging. Contrast Media Mol Imaging (2013) 0.83
Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine (2005) 0.82
The role of non-synaptic extracellular glutamate. Brain Res Bull (2012) 0.82